Articles by Bethan Warman

Impact of chemotherapy on immune cells in the TME

10th April 2021

Research from Barts Cancer Institute, Queen Mary University of London, has revealed novel insights into the effects of chemotherapy on the tumour microenvironment (TME). The study found that chemotherapy enhances the anti-tumour actions of immune cells within the TME and their ability to support immune responses against cancer.

Read more

Combining research and public engagement

8th April 2021

Fran Balkwill, Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, recently wrote a World View article for the journal Nature Reviews Cancer, discussing her dual career in public engagement and research.

Read more

Researchers use machine learning to rank cancer drugs in order of efficacy

25th March 2021

Researchers from Barts Cancer Institute, Queen Mary University of London, have developed a machine learning algorithm that ranks drugs based on their efficacy in reducing cancer cell growth. The approach may have the potential to advance personalised therapies in the future by allowing oncologists to select the best drugs to treat individual cancer patients.

Read more

Ovarian Cancer Perspectives: Q&A with Dr Michelle Lockley

18th March 2021

In recognition of Ovarian Cancer Awareness Month, we spoke with Dr Michelle Lockley, Group Leader and clinical researcher in BCI’s Centre for Cancer Cell and Molecular Biology. Dr Lockley’s research group focuses on improving treatments for women with ovarian cancer, particularly for those whose tumours are resistant to chemotherapy.

Read more

Cancer cell communications

12th March 2021

We spoke with Dr Susana Godinho, Group Leader in Barts Cancer Institute’s Centre for Cancer Cell and Molecular Biology, to find out about her recent paper published in Current Biology. Dr Godinho and her team set out to identify why cancer cells carrying extra centrosomes exhibit increased release of communications packages known as small extracellular vesicles.

Read more

New class of drug reduces risk of death in bladder cancer

15th February 2021

A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Professor Tom Powles from Barts Cancer Institute, Queen Mary University of London and Barts Health NHS Trust.

Read more

Search News